The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer

被引：7
|
作者：
Santana-Davila, Rafael [1 ]
Chow, Laura Q. M. [1 ]
机构：
[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98195 USA
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 03期
关键词：
chemo-immunotherapy; first-line; immune checkpoint inhibitors; immunotherapy; lung cancer; NSCLC; treatment naive; PACLITAXEL PLUS CARBOPLATIN; OPEN-LABEL; PHASE-III; PEMBROLIZUMAB; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB;
D O I：
10.2217/fon-2017-0124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：191 / 194
页数：4
相关论文
共 50 条
  • [1] Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer
    Lin, Wei-Chun
    Chiu, Chao-Hua
    Liou, Jia-Ling
    Chen, Yuh-Min
    Perng, Reury-Perng
    Tsai, Chun-Ming
    LUNG CANCER, 2006, 54 (02) : 193 - 199
  • [2] Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial
    G P Stathopoulos
    J Dimitroulis
    D Antoniou
    C Katis
    D Tsavdaridis
    O Armenaki
    C Marosis
    P Michalopoulou
    T Grigoratou
    J Stathopoulos
    British Journal of Cancer, 2005, 93 : 1106 - 1111
  • [3] Bevacizumab with docetaxel and carboplatin as front-line therapy for non-small cell lung cancer
    Kim, Edward S.
    Ghelani, Dipak
    Kies, Merrill S.
    Blumenschein, George, Jr.
    ANNALS OF ONCOLOGY, 2006, 17 : 234 - 234
  • [4] Docetaxel for locally advanced or metastatic non-small-cell lung cancer current data and future directions as front-line therapy
    Khuri, FR
    ONCOLOGY-NEW YORK, 2002, 16 (06): : 53 - 62
  • [5] Immunotherapies for non-small-cell lung cancer and mesothelioma
    Thomas, Anish
    Hassan, Raffi T.
    LANCET ONCOLOGY, 2012, 13 (07): : E301 - E310
  • [6] Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial
    Stathopoulos, GP
    Dimitroulis, J
    Antoniou, D
    Katis, C
    Tsavdaridis, D
    Armenaki, O
    Marosis, C
    Michalopoulou, P
    Grigoratou, T
    Stathopoulos, J
    BRITISH JOURNAL OF CANCER, 2005, 93 (10) : 1106 - 1111
  • [7] Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer
    Reckamp, Karen L.
    Lin, Huamao M.
    Cranmer, Holly
    Wu, Yanyu
    Zhang, Pingkuan
    Walton, Laura J.
    Kay, Stephen
    Cichewicz, Allie
    Neupane, Binod
    Fahrbach, Kyle
    Popat, Sanjay
    Camidge, D. Ross
    FUTURE ONCOLOGY, 2022, 18 (20) : 2499 - 2510
  • [8] Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer
    Ma, CX
    Nair, S
    Thomas, S
    Mandrekar, SJ
    Nikcevich, DA
    Rowland, KM
    Fitch, TR
    Windschitl, HE
    Hillman, SL
    Schild, SE
    Jett, JR
    Obasaju, C
    Adjei, AA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5929 - 5937
  • [9] Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
    Wolf, Emily
    Sacchi de Camargo Correia, Guilherme
    Li, Shenduo
    Zhao, Yujie
    Manochakian, Rami
    Lou, Yanyan
    VACCINES, 2025, 13 (02)
  • [10] Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer
    Cortes, J
    Rodriguez, J
    Aramendia, JM
    Salgado, E
    Gurpide, A
    Garcia-Foncillas, J
    Aristu, JJ
    Claver, A
    Bosch, A
    Lopez-Picazo, JM
    Martin-Algarra, S
    Brugarolas, A
    Calvo, E
    ONCOLOGY, 2003, 64 (01) : 28 - 35
12345